Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service
- 17 July 2013
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 33 (11) , 1156-1164
Abstract
Study Objective: To determine the procedural feasibility of a pharmacist‐led interdisciplinary service for providing genotype‐guided warfarin dosing for hospitalized patients newly starting warfarin.Design: Prospective observational study.Setting: A 438‐bed tertiary care hospital affiliated with a large academic institution.Patients: Eighty patients who started warfarin therapy and were managed by a newly implemented pharmacogenetics service.Intervention: All patients received routine warfarin genotyping and clinical pharmacogenetics consultation.Measurements and Main Results: The primary outcomes were percentage of genotype‐guided dose recommendations available prior to the second warfarin dose and adherence of the medical staff to doses recommended by the pharmacogenetics service. Of 436 genotype orders placed during the first 6 months of the service, 190 (44%) were deemed appropriate. For the 80 patients on the service who consented to data collection, 76% of the genotypes were available prior to the second warfarin dose. The median (range) time from genotype order to genotype result was 26 hours (7–80 hrs), and the time to genotype‐guided dose recommendation was 30 hours (7–80 hrs). A total of 73% of warfarin doses ordered by the medical staff were within 0.5 mg of the daily dose recommended by the pharmacogenetics consult service.Conclusion: Providing routine genotype‐guided warfarin dosing supported by a pharmacogenetics consult service is feasible from a procedural standpoint, with most genotypes available prior to the second warfarin dose and good adherence to genotype‐guided dose recommendations by the medical staff.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyThrombosis and Haemostasis, 2012
- Emergency Hospitalizations for Adverse Drug Events in Older AmericansNew England Journal of Medicine, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology & Therapeutics, 2011
- Genetic Warfarin DosingJACC, 2011
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLOS Genetics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 EnzymesClinical Chemistry, 2004